監管
Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C
The U.S. FDA approved Merck's LIPFENDRA (enlicitide), the first and only once-daily oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH. In the Phase 3 CORALreef program, LIPFENDRA reduced LDL-C by 56% at week 24 in CORALreef Lipids and by 59% in CORALreef HeFH versus placebo.
大盤 開啟原文 ↗